[1] Ahrens I, et al. FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003. PMID:19705343
[2] Zou F, et al. Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorg Med Chem Lett. 2018 Feb 1;28(3):388-393. DOI:
10.1016/j.bmcl.2017.12.030[3] Roesner JP, et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med. 2009 Feb;37(2):598-605. DOI:
10.1097/CCM.0b013e3181959a12[4] Gr?ger M, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS One. 2009;4(4):e5391. DOI:
10.1371/journal.pone.0005391[5] Aparna Krishnamoorthy, et al. Fibrinogen β–derived Bβ15-42 peptide protects against kidney ischemia/ reperfusion injury. Blood (2011) 118 (7): 1934–1942.